Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.46 |
| ▸ | CCKAR | P32238 | 3/20 | 0.43 |
| ▸ | CCKBR | P32239 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18697474 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL13293965 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL16182631 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL12806533 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24284196 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24198476 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL23051891 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL24899310 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL20911267 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 | |
| SCHEMBL19243816 | 1.00 | GLP1R (0.67) | GLP1RNOD1CCKARCCKBRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840560-B2 | Prodrugs and uses thereof | NOVO NORDISK A/S (DK) | 2023-12-12 | — | — | US | disclosed |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-20 | — | — | US | disclosed |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | NOVO NORDISK A/S (DK) | 2023-05-16 | — | — | US | disclosed |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | NOVO NORDISK A/S (DK) | 2023-05-16 | — | — | US | disclosed |
| US-11352406-B2 | Insulin derivatives and the medical uses hereof | NOVO NORDISK A/S (DK) | 2022-06-07 | — | — | US | disclosed |
| US-20220009989-A1 | BIFUNCTIONAL COMPOUNDS COMPRISING INSULIN PEPTIDES AND EGF(A) PEPTIDES | NOVO NORDISK A/S (DK) | 2022-01-13 | — | — | US | disclosed |
| US-11130794-B2 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2021-09-28 | — | — | US | disclosed |
| US-20200231645-A1 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2020-07-23 | — | — | US | disclosed |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | disclosed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | disclosed |
| US-20110293714-A1 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES | NOVO NORDISK A/S (DK) | 2011-12-01 | — | — | US | disclosed |
| WO-2011131646-A1 | LONG-ACTING GASTRIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2011-10-27 | — | — | WO | disclosed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| US-20110098439-A1 | INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| WO-2010060667-A1 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009115469-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009022013-A1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009022005-A1 | INSULIN ANALOGUES WITH AN ACYL AND ALKYLENE GLYCOL MOIETY | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009022006-A1 | INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840560-B2 | Prodrugs and uses thereof | GIPR, GLP1R, GRPR | GLP1R 2/4885NOD1 687/4885CCKAR 21/4885 |
| US-11649269-B2 | Bifunctional compounds comprising insulin peptides and EGF(A) peptides | IAPP, IGFBP1, IGFBP2 | GLP1R 16/4885NOD1 2091/4885CCKAR 430/4885 |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885NOD1 3929/4885CCKAR 1335/4885 |
| US-11352406-B2 | Insulin derivatives and the medical uses hereof | IAPP, INSR, IRS1 | GLP1R 9/4885NOD1 2706/4885CCKAR 993/4885 |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | GIPR, GLP1R, GRPR | GLP1R 2/4885NOD1 687/4885CCKAR 21/4885 |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | IAPP, INSR, IGF1R | GLP1R 7/4885NOD1 3208/4885CCKAR 250/4885 |
| US-20110098439-A1 | INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS | IAPP, INSR, IGF1R | GLP1R 19/4885NOD1 3838/4885CCKAR 413/4885 |
| US-20110293714-A1 | PHARMACEUTICAL COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION OF DERIVATIZED INSULIN PEPTIDES | IAPP, VIP, INSR | GLP1R 4/4885NOD1 782/4885CCKAR 373/4885 |
| US-11130794-B2 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | GLP1R 1/4885NOD1 743/4885CCKAR 26/4885 |
| US-20200231645-A1 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | GLP1R 1/4885NOD1 743/4885CCKAR 26/4885 |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885NOD1 3929/4885CCKAR 1335/4885 |
| US-20220009989-A1 | BIFUNCTIONAL COMPOUNDS COMPRISING INSULIN PEPTIDES AND EGF(A) PEPTIDES | IAPP, IGFBP1, IGFBP2 | GLP1R 16/4885NOD1 2091/4885CCKAR 430/4885 |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | IAPP, IDE, LIPE | GLP1R 54/4885NOD1 3835/4885CCKAR 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.